Imunon reports FY2024 net loss $18.6M, OS benefit 13mo for IMNN-001, Phase 3 start Q1 2025

Imunon, Inc.

2024-FY EPS reported -$1.62

Net loss $18.6M ($1.62/share) in 2024 vs $19.5M in 2023; cash $5.9M at year-end, sufficient into late Q2 2025.
OVATION 2: median OS 13 months (HR 0.69) with IMNN-001 + chemo vs SOC alone; >1/3 survived >36 months.
Phase 3 pivotal trial of IMNN-001 to begin Q1 2025 after positive End-of-Phase 2 and CMC meetings with FDA.
New CMO Douglas V. Faller, M.D., Ph.D. appointed Feb 18, 2025; leads clinical strategy for IMNN-001.
PlaCCine vaccine Phase 1: IMNN-101 safe, induced 2-4x NAb titers; seeks partners for further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.